诺和诺德Novo Nordisk (NVO) 2010年年度报告「NYSE」.pdf

1、Financial,social and environmental performanceKey fi gures2010 2010 2009 ChangeFinancial performanceSales total DKK million 60,776 51,078 19.0%Diabetes care DKK million 45,710 37,502 21.9%of which modern insulins DKK million 26,601 21,471 23.9%Biopharmaceuticals DKK million 15,066 13,576 11.0%Gross

2、profi t DKK million 49,096 40,640 20.8%Gross margin%of sales 80.8 79.6 Sales and distribution costs%of sales 29.9 30.2 Research and development costs%of sales 15.8 15.4 Administrative expenses%of sales 5.0 5.4 Operating profi t DKK million 18,891 14,933 26.5%Net profi t DKK million 14,403 10,768 33.

3、8%Effective tax rate%21.2 23.0 Capital expenditure,net DKK million 3,308 2,631 25.7%Return on equity(ROE)%39.6 31.3 Free cash fl ow DKK million 17,013 12,332 38.0%Long-term fi nancial targetsOperating profi t growth%26.5 20.7 Operating profi t margin%31.1 29.2 Return on invested capital(ROIC)%63.6 4

4、7.3 Return on invested capital(ROIC)excl non-recurring impact from divestment of ZymoGenetics,Inc.in 2010%62.4 47.3 Cash to earnings(three-year average)%115.6 111.5 Non-fi nancial performanceDonations DKK million 84 83 1.2%Least developed countries where Novo Nordisksells insulin according to the di

5、fferential pricing policy1%67 73 New patent families(fi rst fi lings)Number 62 55 12.7%Employees(total)Number 30,483 29,329 3.9%Employee turnover%9.1 8.3 Energy consumption 1,000 GJ 2,234 2,246(0.5)%Total waste Tons 20,565 21,019(2.2)%Non-fi nancial targetsMaintain a level of engaging culture of 4.0

6、 or above up to 20142 Scale 15 4.3 4.3 Diversity in all 28 senior management teams by 20143%54 50 Water consumption:11%reduction by 2011 compared to 2007%(37)(34)CO2 emissions:10%reduction by 2014 compared to 2004%(55)(31)Share performanceDiluted earnings per share/ADR DKK 24.60 17.82 38.0%Dividend